RNA Editing Lab., Oncohaematology Department, IRCCS Ospedale Pediatrico "Bambino Gesù", Viale San Paolo, 15 00146, Rome, Italy.
Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari "A. Moro", Bari, Italy.
Genome Biol. 2019 Feb 13;20(1):33. doi: 10.1186/s13059-019-1647-x.
Adenosine-to-inosine (A-to-I) RNA editing is an essential post-transcriptional mechanism mediated by ADAR enzymes that have been recently associated with cancer.
Here, we characterize the inosinome signature in normal brain and de novo glioblastoma (GBM) using new metrics that re-stratify GBM patients according to their editing profiles and indicate this post-transcriptional event as a possible molecular mechanism for sexual dimorphism in GBM. We find that over 85% of de novo GBMs carry a deletion involving the genomic locus of ADAR3, which is specifically expressed in the brain. By analyzing RNA editing and patient outcomes, an intriguing gender-dependent link appears, with high editing of Alus shown to be beneficial only in male patients. We propose an inosinome-based molecular stratification of GBM patients that identifies two different GBM subgroups, INO-1 and INO-2, which can identify novel high-risk gender-specific patient groups for which more aggressive treatments may be necessary.
Our data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future personalized targeted gene therapy.
腺苷酸到次黄嘌呤(A-to-I)RNA 编辑是一种由 ADAR 酶介导的重要的转录后机制,最近与癌症有关。
在这里,我们使用新的指标来描述正常大脑和新发胶质母细胞瘤(GBM)中的肌苷组特征,这些指标根据编辑谱对 GBM 患者进行重新分层,并表明这种转录后事件可能是 GBM 性别二态性的一种分子机制。我们发现,超过 85%的新发 GBM 携带 ADAR3 基因组位点缺失,ADAR3 特异性表达于大脑。通过分析 RNA 编辑和患者结局,出现了一个有趣的性别依赖性联系,Alu 的高编辑仅对男性患者有益。我们提出了一种基于肌苷组的 GBM 患者分子分层方法,该方法可识别两种不同的 GBM 亚组,INO-1 和 INO-2,可识别新的高危性别特异性患者群体,可能需要更积极的治疗。
我们的数据提供了正常大脑和 GBM 中 RNA 编辑图谱的详细描述,探讨了 A-to-I RNA 编辑调控,揭示了对 GBM 患者分层和识别性别依赖性高危患者的意外编辑意义,并提出 COG3 I/V 作为未来个性化靶向基因治疗的合适靶点。